Last reviewed 2026-04-20 · How we verify

Ceftazidim

At a glance

Approved indications

• Bacterial infection due to Klebsiella pneumoniae
• Bacterial meningitis
• Bacterial pneumonia
• Bacterial septicemia
• Bacterial urinary infection
• Citrobacter Pneumonia
• Complicated Proteus UTI
• Complicated UTI with Pseudomonas Aeruginosa
• E. Coli Cervicitis
• E. Coli Endometritis
• E. Coli Gynecological Infections
• E. Coli Pelvic Cellulitis
• E. Coli Pelvic Inflammatory Disease
• E. Coli Peritonitis
• Ecthyma gangrenosum
• Endometritis
• Enterobacter Osteomyelitis
• Enterobacter Pneumonia
• EnterobacterJoint Infection
• Escherichia coli urinary tract infection

Common side effects

• Diarrhea
• Nausea
• Vomiting

Serious adverse events

• Death
• Death (CrCl 30-50 mL/min subgroup)

Key clinical trials

• Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations
• Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
• Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
• Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB (PHASE4)
• PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection
• Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE2)
• A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP (PHASE3)
• Oral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.